LONDON, May 18, 2026, 12:00 BST
Advanced Medical Solutions Group shares fell hard Monday after TA Associates confirmed it will not move ahead with a takeover of the British medical supplier. The AIM-listed stock had traded under bid speculation since April. Investegate
That is in focus now because the market had already priced in odds of a deal. A takeover premium had appeared after Advanced Medical Solutions said last month it was talking with TA about a possible full buyout. Investors had added extra value to the shares on hopes a buyer would pay above market price. Advanced Medical Solutions
By 11:44 BST, Barclays Smart Investor quoted the stock at 204.5p to sell and 206.0p to buy, off 16.8% for the session. Shares dipped as low as 187p. They closed at 247p last time. The FTSE AIM All-Share index slipped 0.97%. Barclays
TA put out its statement under Rule 2.8 of the UK Takeover Code — a no intention to bid notice that blocks bidders from making another approach for six months unless exceptions apply or the Takeover Panel allows it. TA kept the door open for another move if Advanced Medical Solutions’ board agrees, if there’s a third-party firm offer, or if circumstances change in a material way. Thetakeoverpanel
Advanced Medical Solutions said its board is still confident in the company’s prospects as a standalone business and its strategy. The company said management plans to keep running the business by itself, without depending on a takeover for value. Advanced Medical Solutions
Withdrawal by TA leaves a gap that’s hard to explain. Reuters said TA didn’t give a reason for pulling out. Panmure Liberum analysts said, “It’s not a good look, and inevitably, the market is going to worry about why PE don’t want to pull the trigger on AMS.” The focus could now shift away from takeover talk to debt, margins, and whether recent acquisitions deliver. Reuters
Advanced Medical Solutions is seeing strong operational momentum. In March, the company posted record 2025 revenue of 228.9 million pounds, a 29% climb. Adjusted EBITDA came in at 49.9 million pounds, up 24%. Adjusted EBITDA excludes tax, financing, and certain non-cash costs. “We have delivered on our key strategic objectives for 2025,” Chief Executive Chris Meredith said. Advanced Medical Solutions
Peters Surgical is one of the tests, a deal that broadened Advanced Medical Solutions’ reach in sutures and specialty surgical products. The company said Peters added 74 million pounds in 2025 revenue. It also reported commercial synergies moving toward the top end of its 5 million to 10 million pound annual target from mid-2029. Advanced Medical Solutions
NIOX Group, a UK-listed medical-device firm, stopped its private sale process in 2025 after Keensight pulled out, showing private-equity demand for smaller healthcare firms sometimes falls short of a deal. That’s another read-across for UK medtech. Reuters
Advanced Medical Solutions will hold its annual general meeting on June 17 in London. Now that the bid is no longer in play, shares may depend on updates from management about Peters integration, cash flow and progress in wound-care and surgical products. Advanced Medical Solutions
